HIV-1 Envelope Stabilizing Mutations for Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccine technologies fail to induce broadly neutralizing antibodies, which are crucial for effective immunity against HIV-1 infection, as existing vaccines do not replicate the conformational stability of the HIV-1 envelope trimer, leading to inadequate immune response.
Innovation Solution
Designing stabilized HIV-1 envelope trimers with specific mutations, such as F14 and Vt8, that mimic the antigenic profile of BMS-626529, to prevent CD4-induced conformational changes and enhance immunogenic properties, and presenting these trimers in a multimeric form, like nanoparticles, to induce a robust immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HIV-1 envelope trimers are stabilized with specific mutations (F14, Vt8) to prevent CD4-induced conformational changes, then the breadth of neutralizing antibody coverage increases, but the complexity of envelope design and manufacturing increases
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations (F14, Vt8) at defined positions in the envelope trimer structure. These mutations alter local structural parameters to stabilize the closed conformation and prevent CD4-induced opening, thereby increasing conformational reliability without requiring complete redesign of the entire envelope system
Solution Approach 2:
The patent copies the stabilizing effect observed with BMS-626529 small molecule binding by introducing mutations that mimic this stabilization. The F14 and Vt8 mutations replicate the conformational stability and antigenic profile achieved by drug-bound trimers, allowing the envelope to maintain its protective closed state without requiring actual drug presence
2Productivity
If envelope trimers are presented in multimeric form (nanoparticles) to enhance immunogenic properties, then the immune response strength increases, but the manufacturing complexity increases
Solution Approach 1:
The patent merges multiple envelope trimers into multimeric nanoparticle structures, combining several immunogenic units into a single vaccine particle. This merging amplifies the immune response through increased antigen density and repetitive display, while the modular nature of the trimers allows for relatively straightforward assembly into larger multimeric structures
3Manufacturing precision
If space filling mutations and layer blocking mutations are introduced to replicate BMS compound effects, then the antigenic profile matching improves, but the manufacturing precision requirements increase
Solution Approach 1:
The patent applies local quality by introducing mutations at specific localized regions of the envelope trimer (F14 at layer 1, Vt8 at the V1/V2-V3 interface). Rather than modifying the entire envelope structure, these localized mutations precisely target the regions involved in CD4 binding and conformational transitions, achieving high antigenic profile matching with focused structural changes
Data Source
AI summary
The technology is directed to HIV envelopes which comprise sequence modifications wherein these modifications prevent CD4-induced transitions of the HIV Env. Provided also are compositions comprising envelopes of the technology, and methods of use.